Market closed
Ocular Therapeutix/$OCUL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ticker
$OCUL
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
274
Website
OCUL Metrics
BasicAdvanced
$1.3B
-
-$1.22
1.33
-
Price and volume
Market cap
$1.3B
Beta
1.33
52-week high
$11.26
52-week low
$4.06
Average daily volume
1.7M
Financial strength
Current ratio
10.664
Quick ratio
10.269
Long term debt to equity
23.419
Total debt to equity
24.032
Interest coverage (TTM)
-12.77%
Management effectiveness
Return on assets (TTM)
-30.52%
Return on equity (TTM)
-95.21%
Valuation
Price to revenue (TTM)
19.621
Price to book
3.95
Price to tangible book (TTM)
3.95
Price to free cash flow (TTM)
-9.196
Growth
Revenue change (TTM)
9.03%
Earnings per share change (TTM)
20.34%
3-year revenue growth (CAGR)
13.55%
3-year earnings per share growth (CAGR)
7.77%
What the Analysts think about OCUL
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.
OCUL Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
OCUL Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
OCUL News
AllArticlesVideos
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Ocular Therapeutix™ to Participate in Two Investor Conferences in April
GlobeNewsWire·4 weeks ago
Ocular Therapeutix Axpaxli Advances In Phase 3 For Wet AMD, Analyst Forecasts Huge Upside
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Ocular Therapeutix stock?
Ocular Therapeutix (OCUL) has a market cap of $1.3B as of April 25, 2025.
What is the P/E ratio for Ocular Therapeutix stock?
The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of April 25, 2025.
Does Ocular Therapeutix stock pay dividends?
No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of April 25, 2025.
When is the next Ocular Therapeutix dividend payment date?
Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocular Therapeutix?
Ocular Therapeutix (OCUL) has a beta rating of 1.33. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.